Innate Pharma (IPHA) News Today $2.25 +0.01 (+0.45%) Closing price 05/6/2025 03:58 PM EasternExtended Trading$2.25 0.00 (0.00%) As of 04:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Innate Pharma announces conference call and webcast for Q1 2025 business updateMay 6 at 1:00 AM | businesswire.comInnate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-FApril 30, 2025 | businesswire.comInnate Pharma Unveils Promising Preclinical Data for IPH4502 at AACR 2025April 29, 2025 | tipranks.comInnate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual MeetingApril 29, 2025 | businesswire.comHC Wainwright Decreases Earnings Estimates for Innate PharmaInnate Pharma S.A. (NASDAQ:IPHA - Free Report) - Equities researchers at HC Wainwright decreased their FY2028 earnings per share estimates for shares of Innate Pharma in a research note issued to investors on Thursday, April 24th. HC Wainwright analyst S. Ramakanth now anticipates that the companApril 29, 2025 | marketbeat.comFY2028 EPS Estimates for Innate Pharma Lowered by AnalystApril 28, 2025 | americanbankingnews.comHC Wainwright Lowers Earnings Estimates for Innate PharmaInnate Pharma S.A. (NASDAQ:IPHA - Free Report) - Investment analysts at HC Wainwright lowered their FY2029 EPS estimates for shares of Innate Pharma in a research note issued on Thursday, April 24th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn $0.53 per share for tApril 27, 2025 | marketbeat.comInnate Pharma FY2029 EPS Estimate Decreased by HC WainwrightApril 27, 2025 | americanbankingnews.comInnate Pharma price target lowered to $11 from $11.50 at H.C. WainwrightApril 25, 2025 | markets.businessinsider.comInnate Pharma Announces €15M Investment by SanofiApril 24, 2025 | businesswire.comInnate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Make a Strategic Investment in the CompanyApril 23, 2025 | businesswire.comInnate Pharma (NASDAQ:IPHA) Trading Up 1.5% - What's Next?Innate Pharma (NASDAQ:IPHA) Trading Up 1.5% - Time to Buy?April 21, 2025 | marketbeat.comInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025April 16, 2025 | businesswire.comInnate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its CompositionApril 16, 2025 | businesswire.comInnate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology ForumApril 3, 2025 | finance.yahoo.comEarnings call transcript: Innate Pharma Q4 2024 sees strategic advancesMarch 29, 2025 | uk.investing.comInnate Pharma S.A. (NASDAQ:IPHA) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | insidermonkey.comInnate Pharma (NASDAQ:IPHA) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $11.50 target price on shares of Innate Pharma in a report on Friday.March 29, 2025 | marketbeat.comInnate Pharma’s Earnings Call Highlights Progress and ChallengesMarch 28, 2025 | tipranks.comInnate Pharma Reports 2024 Financial Results and UpdatesMarch 28, 2025 | tipranks.comInnate Pharma S.A. (IPHA) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comInnate Pharma Reports Full Year 2024 Financial Results and Business UpdateMarch 27, 2025 | businesswire.comInnate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual MeetingMarch 26, 2025 | businesswire.comInnate Pharma announces its participation in the Life Sciences Van Lanschot Kempen ConferenceMarch 25, 2025 | businesswire.comInnate Pharma: Moving Into The Padcev SpaceMarch 21, 2025 | seekingalpha.comInnate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial ResultsMarch 20, 2025 | businesswire.comInnate Pharma S.A. (NASDAQ:IPHA) Sees Significant Increase in Short InterestInnate Pharma S.A. (NASDAQ:IPHA - Get Free Report) saw a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 461,400 shares, an increase of 199.2% from the February 13th total of 154,200 shares. Approximately 0.8% of the shares of the company are sold short. Based on an average daily trading volume, of 677,300 shares, the days-to-cover ratio is presently 0.7 days.March 14, 2025 | marketbeat.comInnate Pharma (NASDAQ:IPHA) Trading Up 1.9% - Should You Buy?Innate Pharma (NASDAQ:IPHA) Trading Up 1.9% - Here's WhyMarch 9, 2025 | marketbeat.comInnate Pharma to Participate in the 2025 Leerink Partners Global Healthcare ConferenceFebruary 27, 2025 | businesswire.comInnate: Lacutamab Treatment Program Moves Forward With Potential ExpansionFebruary 20, 2025 | seekingalpha.comInnate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary SyndromeFebruary 17, 2025 | businesswire.comHC Wainwright Reiterates "Buy" Rating for Innate Pharma (NASDAQ:IPHA)HC Wainwright restated a "buy" rating and set a $11.50 target price on shares of Innate Pharma in a research report on Thursday.February 6, 2025 | marketbeat.comInnate Pharma S.A. (NASDAQ:IPHA) Short Interest UpdateInnate Pharma S.A. (NASDAQ:IPHA - Get Free Report) was the target of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 101,000 shares, a drop of 88.9% from the December 31st total of 909,800 shares. Based on an average trading volume of 467,300 shares, the short-interest ratio is presently 0.2 days.January 28, 2025 | marketbeat.comInnate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid TumorsJanuary 27, 2025 | businesswire.comInnate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New YorkJanuary 21, 2025 | businesswire.comCiti Keeps Their Buy Rating on Innate Pharma (IPHA)January 20, 2025 | markets.businessinsider.comInnate Pharma's (IPHA) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $11.50 price objective on shares of Innate Pharma in a research note on Friday.January 17, 2025 | marketbeat.comInnate Pharma S.A. (NASDAQ:IPHA) Short Interest Down 88.9% in DecemberInnate Pharma S.A. (NASDAQ:IPHA - Get Free Report) was the target of a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 101,000 shares, a decline of 88.9% from the December 15th total of 909,800 shares. Based on an average daily volume of 467,300 shares, the short-interest ratio is currently 0.2 days.January 13, 2025 | marketbeat.comInnate Pharma Announces Transformative Strategy to Accelerate GrowthJanuary 10, 2025 | businesswire.comInnate Pharma S.A. (NASDAQ:IPHA) Short Interest Up 1,344.1% in DecemberInnate Pharma S.A. (NASDAQ:IPHA - Get Free Report) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 909,800 shares, a growth of 1,344.1% from the November 30th total of 63,000 shares. Based on an average daily trading volume, of 461,600 shares, the days-to-cover ratio is presently 2.0 days.December 26, 2024 | marketbeat.comInnate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 20, 2024 | businesswire.comInnate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell LymphomaDecember 9, 2024 | businesswire.comInnate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular LymphomaDecember 6, 2024 | businesswire.comInnate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024December 3, 2024 | businesswire.comInnate Pharma: Looking Like A Company We'll Regret IgnoringNovember 25, 2024 | seekingalpha.comInnate Pharma Releases Its 2025 Financial CalendarNovember 20, 2024 | businesswire.comInnate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501November 19, 2024 | businesswire.comInnate Pharma S.A. (NASDAQ:IPHA) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | msn.comInnate Pharma S.A. (IPHA) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comInnate Pharma Reports Third Quarter 2024 Business Update and Financial ResultsNovember 13, 2024 | businesswire.com Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter. Email Address IPHA Media Mentions By Week IPHA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IPHA News Sentiment▼0.050.69▲Average Medical News Sentiment IPHA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IPHA Articles This Week▼21▲IPHA Articles Average Week Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IMNM News CRON News XERS News AVBP News DNTH News TRVI News ORGO News ABUS News ABCL News KALV News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IPHA) was last updated on 5/7/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
